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Abstract
Background: Interstitial cystitis/painful bladder syndrome (IC/PBS), is a severely debilitating chronic condition that
is frequently unresponsive to conventional pain medications. The etiology is unknown, however evidence suggests
that nervous system sensitization contributes to enhanced pain in IC/PBS. In particular, central nervous system
plasticity of glutamatergic signaling involving NMDA and metabotropic glutamate receptors (mGluRs) has been
implicated in a variety of chronic pain conditions. Here, we test the hypothesis that mGluR5 mediates both non-
inflammatory and inflammatory bladder pain or nociception in a mouse model by monitoring the visceromotor
response (VMR) during graded bladder distention.
Results: Using a combination of genetic and pharmacologic approaches, we provide evidence indicating that
mGluR5 is necessary for the full expression of VMR in response to bladder distention in the absence of
inflammation. Furthermore, we observed that mice infected with a uropathogenic strain of Escherichia coli (UPEC)
develop inflammatory hyperalgesia to bladder distention, and that the selective mGluR5 antagonist fenobam [N-(3-
chlorophenyl)-N’-(4,5-dihydro-1-methyl-4-oxo-1H-imidazole-2-yl) urea], reduces the VMR to bladder distention in
UPEC-infected mice.
Conclusions: Taken together, these data suggest that mGluR5 modulates both inflammatory and non-
inflammatory bladder nociception, and highlight the therapeutic potential for mGluR5 antagonists in the alleviation
of bladder pain.
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Background
Interstitial cystitis/painful bladder syndrome (IC/PBS) is
a serious and painful condition of unknown etiology
that affects 3-6% of women in the United States [1,2].
The major clinical symptom of IC/PBS is pain upon
bladder filling (distention) leading to urinary frequency
and urinary urgency [3]. The current available treat-
ments are often ineffective and do not treat the underly-
ing pathology. Rodent bladder-injury models that induce
some of the symptoms observed in IC/PBS have been
used to evaluate potential treatments for IC/PBS [4-9].
One injury model, bacterial cystitis (urinary tract infec-
tion, UTI) is known to cause a similar constellation of
symptoms as observed in IC/PBS (i.e. urinary frequency
and urgency [10-12]). In addition, bacterial cystitis can
be modeled in rodents through bladder exposure to uro-
pathogenic Escherichia Coli (UPEC) [13,14]. Bladder
infections due to UPEC are responsible for approxi-
mately 80% of UTIs in otherwise healthy women
[15,16]. Understanding the underlying molecular
mechanisms of both non-inflammatory bladder pain and
inflammatory bladder pain due to UPEC infection could
lead to the development of novel treatments for painful
bladder infections as well as for IC/PBS and possibly
other visceral pain conditions.
Glutamate is the predominant excitatory neurotrans-
mitter in the mammalian nervous system [17-19]. Gluta-
mate mediates its effects through two major classes of
glutamate receptors: ligand-gated ionotropic receptors
(iGluRs) and G protein-coupled metabotropic glutamate
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receptors, one subtype, mGluR5, is of particular interest
in the context of pain conditions. mGluR5 is expressed
throughout the peripheral and central nervous system
[20] and has previously been shown to have a pro-noci-
ceptive role in a variety of somatic pain models [20-25]
and some visceral pain models [26-28]. Specific to visc-
eral pain models, mGluR5 was found to modulate gas-
troesophogeal and colorectal afferent sensitivity
[26,27,29]. Based on this prior information, a previous
study examined the ability of the mGluR5 antagonist,
MPEP (2-methyl-6-(phenylethynyl)-pyridine), to reduce
bladder pain responses in naïve (uninjured) rats [30].
While this study suggests a potential role for mGluR5 in
bladder pain, the evidence is based exclusively on the
use of MPEP, which has recently been shown to act
non-selectively in vivo [31]. Thus, these intriguing initial
findings are in need of validation. Furthermore, the role
of mGluR5 in inflammatory bladder pain is unknown.
Here, using a combination of genetic and pharmacologi-
cal approaches we demonstrate that mGluR5 regulates
both bladder nociception and normal bladder function
in naïve mice. Furthermore, we observed an increased
VMR to bladder distention in mice infected with UPEC.
Finally, UPEC-induced hyperalgesia is reduced by treat-
ment with the specific mGluR5 antagonist, fenobam.
Together these data strongly support the hypothesis that
mGluR5 is necessary for the full expression of inflam-
matory and non-inflammatory bladder nociception and
may be a relevant target for the treatment of bladder
pain arising from multiple pathologies, including IC/
PBS.
Results
mGluR5 is necessary for the full expression of non-
inflammatory bladder nociception
To assess bladder nociception in response to distension,
we utilized the distension-evoked visceromotor response
(VMR). The VMR is a spinobulbospinal reflex to blad-
der distention, increased in decerebrate mice/rats and
absent in mice/rats with an acute mid thoracic spinal
cord transection [32-34]. Bladder distention reliably pro-
duces pain and/or discomfort in humans [35], and is
frequently used in rodents as a visceral pain model
[5,30,33]. To provide genetic evidence supporting a role
for mGluR5 in bladder nociception, we tested the VMR
to bladder distention in mGluR5 knockout mice
(mGluR5 KO) compared to their WT littermates. Step-
wise increases in bladder distension resulted in progres-
sively larger VMR in wild type mice, as shown in Figure
1B. Furthermore, mGluR5 KO mice showed a statisti-
cally significant decrease in the evoked response to blad-
der distention (VMR) in the noxious range of pressures
when compared to the VMR of WT littermates (p <
0.0001).
There are several possible reasons that genetic abla-
tion of mGluR5 could lead to the observed suppression
of the VMR. Recent work has implicated the urothelium
in the sensation of physical and chemical stimuli [36].
One possibility is that loss of mGluR5 could lead to ana-
tomical changes in the bladder lining, thus altering the
response to distension. We therefore examined histolo-
gical sections from mGluR5 KO mice and their WT lit-
termates. The absence of mGluR5 does not appear to
impact bladder architecture, as the bladders from
mGluR5 KO mice are histologically indistinguishable
from WT littermates. The superficial, intermediate and
basal epithelial cells are present (see Figure 1C and 1D)
and the underlying mesenchyme and muscle layers also
remain intact. Furthermore, the barrier formed by the
superficial cells is normal as evidenced by Uroplakin III
staining (data not shown) in both the WT and mGluR5
KO mice. Therefore, the absence of mGluR5 affects the
response to noxious bladder distention but does not
alter gross urothelial architecture.
Compensatory changes in gene expression represent a
potential confound to any experiment utilizing genetic
manipulation. Thus, the robust phenotype observed in the
mGluR5 KO mice could be the result of compensatory
expression changes in other genes that have a role in blad-
der nociception. An acute pharmacological blockade of
the receptor represents a potentially powerful approach to
complement these findings from genetically modified
mice. However, as mentioned above, the pharmacologic
agent (MPEP) used in prior studies shows a clear lack of
specificity in vivo [31]. To ask whether mGluR5 activation
is acutely involved in distention-induced bladder nocicep-
tion, we tested whether specific pharmacologic inhibition
of mGluR5 with the selective antagonist fenobam
[31,37,38], would suppress the VMR to urinary bladder
distention. Systemic (intraperitoneal (IP)) administration
of fenobam to WT mice resulted in a statistically signifi-
cant reduction in the response to bladder distention com-
pared to pretreatment baseline responses (Figure 2B, p <
0.0001), whereas treatment with vehicle had no statistically
significant effect on VMR compared to baseline (Figure
2A). Thus, pretreatment with fenobam mimicked the
reduced nociceptive response to bladder distention that
was observed in mGluR5 KO mice relative to their WT lit-
termates (compare Figure 1A and 2A). We next evaluated
the effect of fenobam on the VMR of mGluR5 KO mice.
Surprisingly, treatment with either vehicle (DMSO) or
fenobam caused a small but statistically significant
decrease in the VMR evoked by bladder distention com-
pared to baseline responses in mGluR5 KO mice (Figure
2C and 2D, p < 0.001 and p = 0.007).
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Figure 1 Reduced visceromotor response to bladder distension in mGluR5 knockout mice compared to wild type littermates. A.
Representative VMR tracings from a WT and mGluR5 KO mice. As the intravesicular pressure is increased (20-80 mmHg), the EMG activity of the
abdominal muscle (VMR) is also increased. The total amount of activity (area under the curve) during the 20 second distention is calculated to
determine the evoked response at each pressure. B. mGluR5 KO (n = 18) mice have a significantly blunted VMR when compared to WT
littermates (n = 15) +/- SEM,* p < 0.05, **p < 0.01, ***p < 0.001. 2-way ANOVA with Bonferroni post-hoc test. There were no obvious histological
differences observed between mGluR5 KO mice (1D) and their WT littermates (1C). In both, the urothelium (above dashed line) has normal layers
of superficial facet cells (arrows), intermediate cells (black arrowhead) and basal cells (white arrowhead).
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To test the role of mGluR5 in urodynamics, we com-
pared the cystometry profile of mGluR5 KO mice and
their WT littermates. mGluR5 KO mice had a signifi-
cantly increased IMI (212.3 seconds versus 471.5 sec-
onds, for WT and KO, respectively, p = 0.0006) (Figure
3A-C). Despite the difference in IMI, the average ampli-
tude of bladder contractions was not significantly differ-
ent in mGluR5 KO mice relative to their WT
littermates (Figure 3D, p = 0.9215).
To determine if the voiding behavior we observed in
mGluR5 KO mice was the result of genetic ablation of
mGluR5 or the result of compensatory changes, we
acutely treated WT mice with fenobam or vehicle and
measured the effect on urodynamics. While vehicle
treatment had no effect on IMI (160.2 seconds versus
177.1 seconds, for baseline and vehicle (DMSO) respec-
tively, p = 0.66, Figure 4D), fenobam treatment
increased the IMI when compared to the baseline IMI.
The IMI before fenobam treatment was 182 seconds (n
= 8). After IP fenobam treatment, four of the eight mice
stopped bladder cycling and micturition immediately
( F i g u r e4 C ) ,w h i l ef o u ro ft h em i c eh a ds i g n i f i c a n t l y
increased IMI (481.3 seconds, p = 0.031, Figure 4D and
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Figure 2 The selective mGluR5 antagonist, fenobam, is analgesic in distention-induced bladder pain model. A. Treatment with the
vehicle used to dissolve fenobam (100% DMSO) has no effect on the response to bladder distention. B. Treatment with an mGluR5 antagonist,
fenobam, is analgesic in a bladder distention-evoked pain model. C&D. Fenobam and DMSO reduce the evoked response in mGluR5 KO mice.
+/- SEM,* p < 0.05, **p < 0.01, ***p < 0.001. 2-way ANOVA with Bonferroni post-hoc test.
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Page 4 of 134E). The mean time to resume bladder cycling and mic-
turition after systemic fenobam administration was 18.6
minutes. This suggests a tight coupling between
mGluR5 activation and micturition cycling. The acute
effect of the mGluR5 antagonist also suggests that the
increased IMI observed in mGluR5 KO mice is not
likely due to developmental changes as a result of
genetic ablation of mGluR5.
UPEC infection results in changes in bladder histology
and an increased VMR
Our results, together with previous studies [30,39,40]
suggest that mGluR5 is involved in the mediation of
micturition cycling and controls nociceptive responses
during noxious bladder distention; however, the role of
mGluR5 in inflammatory bladder nociception is unex-
plored. We therefore used the UPEC model of bladder
inflammation to examine the role of mGluR5 in inflam-
matory bladder nociception. We found that UPEC infec-
tion resulted in an increased VMR to noxious bladder
distention when compared to mock-infected littermate
controls (Figure 5A, p < 0.0001). Furthermore, in mice
whose bladders had been distended, UPEC infection
produced an increased infiltration of polymorphonuclear
leukocytes observed throughout the full thickness of the
bladder tissue (Figure 5B, arrowheads), as well as an
increased tissue thickness of both the urothelium and
mesenchyme compared to distended mock-infected
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Figure 3 mGluR5 KO mice have an increased intermicturition interval. A. Representative urodynamic profile of a WT mouse. B.
Representative urodynamic profile of a mGluR5 KO mouse. A-C. The IMI in WT mice was significantly smaller when compared to mGluR5 KO
mice (WT baseline IMI 212.3 ± 12.94 N = 3, mGluR5 KO IMI baseline 471.5 ± 29.14 N = 5). D. However, there was no difference in the bladder
contraction amplitude. ***P < 0.001 unpaired Student’s t-test compared to WT IMI.
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Page 5 of 13mice (Figure 5C). Noxious bladder distention combined
with UPEC infection resulted in greater histological
damage as measured by tissue inflammation scores
when compared to mock-infected mice with noxious
distention (data not shown) [41]. UPEC infection (alone
and with distention) resulted in barrier disruption
through a loss of superficial facet cells, while noxious
distention alone had no effect on these cells and the
barrier remained intact (arrows, Figure 5C).
mGluR5 is necessary for the full expression of
inflammatory bladder nociception
In mice with a UPEC-induced UTI, mice treated with
vehicle had an increased VMR when compared to
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Figure 4 Fenobam treatment increases the intermicturition interval. A-C. Representative urodynamic profile of WT mice before and after
treatment. An intraperitoneal (IP) injection with fenobam significantly increased the IMI in 4/8 mice treated (B, E), while 4/8 mice stopped
cycling (C). In the mice that stopped cycling, the mean time to resume bladder cycling and micturition after IP fenobam administration was 18.6
± 5.0 minutes. The IMI was not significantly affected by IP DMSO (n =7 )( A, D). *P < 0.05 paired Student’s t-test compared to baseline.
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Figure 5 UPEC Infection results in histological changes and bladder hyperalgesia. A. 24 hour infection with uropathogenic E. coli (UPEC)
increases the VMR to bladder distention when compared to mock-infected (PBS) littermates. B. Infection with UPEC results in an increased
infiltration of polymorphonuclear leukocytes (arrowheads), and a sloughing of the superficial facet cells. C. Distention alone does not result in the
loss of superficial facet cells (arrows,). +/- SEM *p < 0.05, **p < 0.01, ***p < 0.001. Unpaired 2-way ANOVA with Bonferroni post-hoc test.
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Page 7 of 13baseline (Figure 6A, p = 0.0007). While vehicle treat-
ment increased the VMR, treatment with fenobam
resulted in a significantly reduced VMR when compared
to pre-fenobam measurements (Figure 6B, p = 0.0006).
In contrast, vehicle had no effect on the VMR in mice
mock infected (with PBS instead of UPEC, Figure 6C).
In these control mice (mock infected), treatment with
fenobam significantly reduced the VMR when compared
to pre-treatment VMR measurements (Figure 6D).
These results are consistent with those observed in WT
mice (not mock-infected, Figures Error! Reference
source not found. A and 2B).
Discussion
Clinically, visceral pain is often treated as a variant of
somatic pain under the assumption that one neurologi-
cal mechanism may be responsible for both visceral and
somatic pain [42]. However, conventional treatments for
somatic pain are often ineffective in treating visceral
pain, indicating significant differences between visceral
and somatic pain [42,43]. This is likely due, in part, to
intrinsic differences between visceral nociceptors and
non-visceral nociceptors (Reviewed in: [43-45]). Our
results support this difference as we found that blocking
mGluR5 activation resulted in a decreased VMR in the
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Figure 6 Treatment with an mGluR5 antagonist, fenobam, is analgesic in a UPEC infection-induced inflammatory bladder distention-
evoked pain model. Treatment with the vehicle used to dissolve fenobam (100% DMSO) increases the evoked response to bladder distention
(A, n = 5), whereas treatment with fenobam significantly reduced the evoked response to bladder distension (B, n = 7). In mock-infected
animals, treatment with the vehicle used to dissolve fenobam (100% DMSO) had no effect on the evoked response (C, n = 6), whereas fenobam
significantly reduced the evoked response (D, n = 6). * p < 0.05, **p < 0.01, ***p < 0.001. Paired 2-way ANOVA with Bonferroni post-hoc test
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Page 8 of 13absence of injury. Whereas previous work has demon-
strated that blocking mGluR5 activation has no effect
on somatic pain in the absence of injury [31,46].
Although the role of mGluR5 in inflammatory bladder
pain is unclear, a few reports have shown that mGluR5
antagonism can lead to analgesia in visceral pain models
(acetic acid writhing and colonic distention)
[23,24,27,30,37,47-49]. A recent publication reported
that an mGluR5 antagonist, MPEP, effectively reduced
the nociceptive VMR to noxious distention of non-
inflamed bladders in rats [30]. However, MPEP, has
since been shown to have off-target effects, as it retains
analgesic efficacy in mGluR5 KO mice [31]. Thus, the
precise role of mGluR5 in bladder distention-induced
nociception remains unclear. Further, it is unknown
whether mGluR5 activation has a role in the more clini-
cally relevant condition of inflammatory bladder pain. In
the present study, we demonstrate that mGluR5 is
necessary for the full expression of distention-induced
bladder nociception in naïve as well as UPEC-infected
mice.
Here, we demonstrate the importance of mGluR5 in
non-inflammatory bladder nociception using both
genetic and pharmacologic techniques. First, mice lack-
ing mGluR5 have a significantly reduced response to
noxious bladder distention when compared to their WT
littermates. Despite this dramatic effect, mGluR5 KO
mice have no baseline motor deficiencies [50]. However,
genetic deletion of mGluR5 could result in unpredict-
able upregulation or compensation of other genes
involved in bladder function. Acute systemic treatment
with a selective mGluR5 antagonist (fenobam) mimics
the blunted VMR observed in the mGluR5 KO mice,
suggesting that the absence of mGluR5 activity accounts
for the differences in VMR as well as the cystometric
profile observed in mGluR5 KO mice. Together these
data suggest that mGluR5 is necessary for the full
expression of distention-induced bladder pain in naïve
mice and highlight the therapeutic potential for mGluR5
antagonists in the treatment of bladder pain.
Surprisingly, both fenobam and vehicle (DMSO)
induced a small but statistically significant reduction in
the distention induced VMR in mGluR5 KO mice.
Fenobam at the dose used in this study was previously
demonstrated to be specific to mGluR5 in vivo [31], and
we do not believe that these results challenge that find-
ing because fenobam but not DMSO, had an effect on
the VMR of WT mice. Because both fenobam and vehi-
cle significantly reduced the VMR in mGluR5 KO mice,
we conclude that the vehicle is having effects in the KO
that are not observed in WT mice. A possible explana-
tion for the effects of the DMSO in KO but not in WT
mice is that mGluR5 KO mice are significantly smaller
than their WT littermates [51]. DMSO has been shown
to block peripheral C-fiber nerve conduction [52]. It is
possible that the volume (20 μl) delivered in relation to
the weight of the mGluR5 KO mice leads to such a con-
duction block.
The dramatic phenotype of mGluR5 KO mice as well
as the significantly reduced pain response in fenobam-
treated WT mice suggests that mGluR5 regulates blad-
der nociception. It is also possible that mGluR5 could
regulate normal bladder function such as micturition.
To examine the role of mGluR5 in normal bladder func-
tion, we examined the cystometric profiles of mGluR5
KO mice compared to their WT littermates. Genetic
disruption of mGluR5 significantly increased the IMI,
but had no effect on the bladder contraction amplitude
(pressure at which voiding occurred). An increased IMI
suggests that mice lacking mGluR5 are able to urinate,
but they tolerate higher bladder volumes (i.e.h i g h e r
bladder distension) before voiding. Our results are con-
sistent with previous work demonstrating a role for
mGluR5 in the micturition reflex [30,39,40]. Impor-
tantly, mGluR5 does not appear to be involved in blad-
der development, as bladders of mGluR5 KO mice were
indistinguishable from their WT littermates upon gross
inspection. These results suggest that mGluR5 has a
role in bladder sensation in naïve mice.
Bladder infections due to UPEC are the most common
reason that women see a doctor [11,53]. This is the first
evidence that infection with UPEC sensitizes mice to
noxious bladder distention. WT mice infected with
UPEC had a greater VMR to bladder distention when
compared to mock-infected littermate controls. These
data are consistent with the finding that mice with a
UTI have increased referred abdominal pain [54].
Furthermore, our results indicate that pharmacologic
blockade of mGluR5 activation can reduce the VMR to
bladder distention in UPEC-infected mice. The reduc-
tion in the distention-evoked VMR after fenobam treat-
ment in mice infected with UPEC may be even larger
than is apparent in Figure 6B, as the VMR is actually
increased in vehicle-treated mice (see Figure 6A).
Because distention in combination with UPEC infection
was more damaging to bladder histology than distention
in mock infected mice, the increased VMR after vehicle
is likely the result of injury induced by bladder infection
in combination with repeated noxious bladder disten-
tion. Another, yet unlikely, explanation is that systemic
DMSO might lead to bladder sensitization in mice with
UPEC infection.
In models of somatic inflammatory pain, an increase
in mGluR5 expression was observed in the CNS, specifi-
cally the central nucleus of the amygdala and the spinal
cord [55,56]. Whether mGluR5 expression is altered in
the context of visceral inflammatory pain remains to be
determined.
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Up to 85% of community-acquired UTIs are due to
infection with UPEC [57,58]. Standard-of-care for a UTI
is antibiotic treatment. However, in women with normal
urological anatomy (uncomplicated UTI), UTIs are self-
limiting [16]. Therefore, uncomplicated UTIs will
resolve without antibiotic treatment. Despite this, the
pain due to a UTI necessitates antibiotic treatment for
symptomatic relief. Antibiotic use can lead to UTI
recurrence by selecting for antibiotic resistant bacteria
[16]. By treating the pain of a UTI rather than the infec-
tion, it may be possible to allow the UTI to take its nat-
ural course and become self-limited and reduce
antibiotic-resistant reoccurrence. Based on our findings,
we suggest that mGluR5 antagonists could be a useful
for therapy for symptomology in UTI that could reduce
antibiotic use.
Although less common, bladder pain in the form of
IC/PBS is a serious and debilitating medical condition.
Unfortunately for patients, no reliably effective treat-
ment options exist. Previous work has suggested a role
for mGluR5 in the CNS in distention-induced bladder
pain [30]. However, the mGluR5 antagonist used in this
study (MPEP) is analgesic in mGluR5 KO mice, suggest-
ing off-target effects [31]. Here, using a combination of
genetics and pharmacology, we demonstrate that
mGluR5 has a crucial role in the modulation of disten-
tion induced bladder nociceptive responses. Because in
these studies mGluR5 was blocked systemically and
knocked out globally, the anatomical localization where
mGluR5 modulates bladder pain is undefined. In addi-
tion, mGluR5 is expressed throughout the peripheral
and central nervous system [20,21,46,59-62]. However, it
should be noted that the mGluR5 antagonist, fenobam,
readily and rapidly crosses the blood brain barrier [31].
If the chronic pain experienced due to IC/PBS is also
mediated by mGluR5, then antagonists of mGluR5 such
as fenobam may be useful in treating chronic bladder
pain. Antagonists of mGluR5 may have clinical potential
for the treatment of both acute and chronic bladder
pain. Previous work using non-visceral pain models has
demonstrated that mGluR5 activity modulates the acti-
vation of ERK1/2 (extracellular regulated kinase 1/2) in
both the spinal cord [25,63] and/or central nucleus of
the amygdala (CeA) [46,64]. Inhibition of mGluR5 in
the CeA is analgesic in multiple models of somatic
inflammatory pain [46,60]. Furthermore, recent work
from our lab has demonstrated that inhibition of spinal
ERK signaling via intrathecally administered MEK inhi-
bitors is analgesic in both inflammatory and non-inflam-
matory bladder pain models [5]. Future work can help
determine the anatomical and molecular mechanisms by
which mGluR5 modulates bladder nociceptive responses.
Methods
1. Subjects and ethical approval
All animal experiments were performed in accordance
with the guidelines of the Committee for research and
Ethical Issues of International Association for the Study
of Pain [65]. The experimental protocol was approved
by the Washington University Institutional Animal Care
a n dU s eC o m m i t t e e( S t .L o u i s ,M O ) .A l le x p e r i m e n t s
were performed on female mice aged 10-13 weeks. All
mice were humanely euthanized at the end of the
experiments by decapitation under deep isoflurane (5%)
anesthesia. Female C57BL/6 mice used in UPEC experi-
ments were purchased from The Jackson Laboratory
(Bar Harbor, ME). For experiments involving mice lack-
ing mGluR5 (mGluR5 KO), animals were bred in-house
on a C57BL/6 background and compared with wildtype
(WT) littermates [50]. Unless otherwise indicated, all
mice were group housed in cages of 3-5. All mice were
kept on a 12:12-h light/dark schedule with ad libitum
access to food and water.
2. Drugs and other agents
Fenobam was purchased from Tocris Bioscience (Ellis-
ville, MO), and is a specific negative allosteric modulator
of mGluR5 [31,38]. The dosage (30 mg/kg, intraperito-
neal) of fenobam was chosen because it was the lowest
effective dose to induce analgesia in two mouse models
of inflammatory pain, and had no effect on mGluR5 KO
mice [31]. Fenobam was dissolved in 100% dimethyl
sulfoxide (DMSO, Sigma-Aldrich, St. Louis, MO) on the
day of the experiment. All intraperitoneal injections
were 20 μl. Throughout all experiments and analysis,
the investigator performing the VMR was blinded to
pharmacological treatment.
3. Phasic bladder distentions and VMR measurements
Visceral nociception was quantified using VMR, an
electromyographic (EMG) recording of the abdominal
muscle response to bladder distention that has pre-
viously been validated as a measure of nociception
[34,66]. An example of the bladder-distention induced
VMR of WT mice can be seen in Figure 1. Abdominal
VMRs to urinary bladder distention were performed as
described previously [5]. The mice were anesthetized
with 2% isoflurane, and chlorinated silver wire electro-
des were placed on the superior oblique abdominal
muscle. One was placed subcutaneously across the
abdominal wall (as a ground) to allow differential ampli-
fication of the abdominal VMR signals. A lubricated
24G angiocatheter was inserted into the bladder via the
urethra for bladder distention. After completion of the
surgical preparation, isoflurane anesthesia was reduced
to approximately 0.9% until a flexion reflex response
was present (evoked by pinching the paw) but sponta-
neous escape behavior and righting reflex were absent.
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was not changed for the duration of the experiment.
The animals were not restrained in any fashion. Body
temperature was monitored throughout the experiment
and maintained using an overhead radiant light. Phasic
bladder distention with compressed air was then used to
evoke a VMR. The air pressure was controlled by an
automated distention control device custom made in the
Washington University School of Medicine Electronics
Shop. The distention stimulus applied 20 to 80 mm Hg
pressure (10 mmHg steps) for 20 seconds every 2 min-
utes. The VMR signal was relayed in real time using a
Grass CP511 preamplifier (Grass Technologies, West
Warwick, RI) to a PC via WinDaq DI-720 module
(Dataq Instruments, Arkon, OH). These data were
exported to Igor Pro 6.05 software (Wavemetrics, Port-
land, OR). Using a custom script, the VMR signals were
subtracted from the baseline, rectified, and integrated
over 20 seconds to quantify the area under the curve
(see Figure 1). The VMR is presented in arbitrary units.
After baseline responses to distensions 20 mmHg-80
mmHG (10 mmHg steps) were recorded, the mouse was
allowed to recover for at least 30 min (level of anesthe-
sia remained unchanged). Following baseline recordings,
t h em i c ew e r eg i v e na2 0u lI Pi n j e c t i o no fe i t h e rf e n o -
bam (30 mg/kg, dissolved in 100% DMSO) or 100%
DMSO (vehicle). A second set of bladder distentions (20
mmHg-80 mmHg, 10 mmHg steps) was started 5 min-
utes following administration of fenobam or vehicle and
completed within 45 minutes. The investigator who
tested, processed and quantified the VMR was blinded
to the drug treatment and genotype.
4. Infection with UPEC
Infection with a clinical UPEC isolate, UTI89, was per-
formed as previously described [67]. Briefly, mice were
anesthetized with isoflurane and inoculated via transure-
thral catheterization with 50 μlo f2 - 8×1 0
7 colony-
forming units/mL of bacteria in phosphate buffered sal-
ine (PBS). Control mice (mock-infection) received 50 ul
of intravesicular PBS. Following intravesicular instilla-
tion of either PBS or UPEC, the mice were individually
housed. Urine was collected at 6 and 24 hours, and
infection was confirmed. At 24 hours post infection, the
VMR response to bladder distention was recorded as
previously described [5]. Following the VMR, isoflurane
anesthesia was increased and the mice were euthanized
by cervical dislocation. Bladder tissue was quickly
removed and fixed in methacarn (60% methanol, 30%
chloroform, 10% glacial acetic acid) [13]. The bladder
tissue was then embedded in paraffin, sectioned and
stained with hemotoxylin and eosin. Photomicrographs
were taken using a Hamamatsu NanoZoomer HT
(Hamamatsu Corporation).
5. Urodynamics
Urodynamic recordings were performed as described
previously [68]. Briefly, mice were anesthetized with sub-
cutaneous urethane (1.2 g/kg). A midline laparotomy
incision was made, and the dome of the urinary bladder
was exposed. The bladder dome was punctured with a
25-gauge needle. Intravesicular pressure was monitored
continuously in vivo while the bladder was filled with
room temperature saline at a rate of 0.04 mL per minute
using a syringe pump (KD Scientific, New Hope, PA).
Voiding was allowed to occur spontaneously via the ure-
thra. The intravesicular pressure was recorded in real
time using WINDAQ data acquisition program (DataQ
Instruments, Akron, OH) at a sampling rate of 20 Hz.
The intermicturition interval (IMI) was calculated as the
average time (seconds) between peaks. The amplitude of
contraction was the value (cmHg) of the peak.
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